We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Biotech Presents Sustainable Lab Solutions with Unlimited Possibilities at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: Getein’s POCT testing solutions meet the different needs of laboratory detection (Photo courtesy of Getein Biotech)
Image: Getein’s POCT testing solutions meet the different needs of laboratory detection (Photo courtesy of Getein Biotech)

Getein Biotech, Inc. (Nanjing, China) is presenting its sustainable diagnostic solutions that offer unlimited possibilities for laboratories at the 2022 AACC Clinical Lab Expo.

AT AACC 2022, Getein will exhibit its range of POCT immunofluorescence quantitative analyzers, including the Getein1160, Getein1180, Getein1200 and Getein1600. These immunofluorescence quantitative analyzers automate the detection and quantification of markers for cardiovascular diseases, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor, and thyroid in biological samples. Getein is also showcasing the MAGICL6000 chemiluminescence immunoassay analyzer that automates the detection and quantification of markers for thyroid disease, inflammation, cardiac diseases, fertility, diabetes mellitus, bone metabolism, tumor, infectious disease, anemia, and immune globulin by analyzing human serum, plasma, whole blood and urine samples.

In addition, Getein will exhibit the fully automated CM-400 clinical chemistry analyzer for the quantitative analysis of chemical components in human serum, plasma, whole blood, urine, and cerebrospinal liquid samples. CM-400 is characterized by open reagents, discrete system, emergency priority, random access and an external computer. The analyzer consists of the main instrument and the computer with the main instrument composed of an optical system, reaction system, sample adding system, reagent adding system, cleaning system and mixing system, with an optional electrolyte module.

Getein is also highlighting the BHA-3000 and BHA-5000 automatic hematology analyzers that provide quantitative analysis of a patient's blood components at high speed with accuracy, alongside the XN06 semi-automated blood coagulation analyzer for testing four routine clotting test items, namely PT, TT, APTT and FIB. Getein will demonstrate its One Step Test for SARS-CoV-2 Antigen (Colloidal Gold) for the qualitative detection of SARS-CoV-2 antigens in human nasal swab samples. The test is suitable for medical laypersons as a self-test at home or at work. Getein provides a comprehensive range of COVID-19 testing solutions, including neutralizing antibody tests, antigen tests and IgM/IgG antibody tests. Getein also offers the Monkeypox Virus Real-time PCR Kit for the qualitative detection of MPV in serum or lesion exudate samples.
 

Related Links:
Getein Biotech, Inc. 

New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Adenovirus Test
S3334E ADV Adenovirus Kit
New
Epstein-Barr Virus Test
ZEUS IFA Epstein-Barr Virus VCA IgG Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The kit includes a container with a film, a compact optical device for attaching a smartphone, and a diagnostic app (Photo courtesy of KIST)

Urine-Based Bladder Cancer Diagnostic Kit to Reduce Need for Unnecessary Cystoscopies

Bladder cancer has a high cure rate of over 90% when detected early, but it is characterized by a recurrence rate of 70%, which requires continuous monitoring. Late-stage detection often results in major... Read more

Microbiology

view channel
Image: The QIAstat-Dx mini gastrointestinal panel has secured U.S. clearance to support year-round outpatient care (Photo courtesy of QIAGEN)

Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions

Acute infectious gastroenteritis is a major cause of outpatient visits and hospitalizations in the U.S., with over 179 million cases estimated annually. Now, a new gastrointestinal panel designed to provide... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.